Stockreport

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration [Yahoo! Finance]

Outlook Therapeutics, Inc.  (OTLK) 
Last outlook therapeutics, inc. earnings: 2/14 08:00 am Check Earnings Report
PDF company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab [Read more]